The biotech industry treats speed as an intrinsic good. But let’s be clear: acceleration is not intrinsically valuable. Speed only creates value when paired with control, feedback, and clear ownership. Movement without these is unmanaged risk. A trial can enroll faster if you loosen criteria. A database can lock faster if you skip verification. A decision can be made faster if you do not consult the right people. None of these create better outcomes. True acceleration requires clarity of intent, defined decision rights, and explicit tradeoffs. Control is not friction. It is the foundation that allows motion.
KEY TAKEAWAYS
Key Takeaways
- Speed without control creates unmanaged risk, not acceleration.
- True acceleration requires clarity of intent and defined decision rights.
- Control mechanisms are the foundation for sustainable motion in clinical programs.
- Every shortcut in enrollment, database work, or governance carries hidden costs.
The Cost of Velocity Without Vision
Kieran Engels and the teams at Seuss+ spend much of their time watching programs stumble not because they are slow, but because they are moving without intention. Speed becomes a substitute for strategy. Timelines compress. Decision-making accelerates. But the governance infrastructure that gives decisions meaning does not accelerate. The result: velocity masquerading as progress.
This is the paradox that undoes many programs. When a CRO can enroll subjects faster by relaxing inclusion criteria, you gain speed and lose signal integrity. When a database team locks the schema faster by skipping verification steps, you meet a deadline and inherit data quality issues that resurface in analysis. When leadership makes a decision faster by excluding stakeholder input, you accelerate in the moment and decelerate later when rework begins.
The Architecture of Controlled Motion
The truth is: the fastest programs we have seen are not the ones that skip steps. They are the ones that are intentional about which steps matter. They establish clear ownership early. They define success before execution begins. They measure progress against those definitions. They course-correct without defensiveness. This is what control looks like. Not bureaucracy. Not friction. Clarity.
Consider enrollment acceleration. Programs often approach it as a volume problem. More sites. More advertising. More outreach. But the fastest enrollment happens when you know exactly who your subject is, where to find them, and why they will choose your trial. It is not faster because it is louder. It is faster because it is precise. That precision is a governance output, not a trial operations output.
Three Data Points on the Hidden Cost of Speed
First: Programs that skip baseline verification to accelerate study start experience a 40 percent higher rate of protocol deviations in the first 90 days. The speed gain is erased before the trial matures.
Second: CRO performance issues that arise from unclear governance frameworks take four times longer to resolve than governance misalignment between Seuss+ partners and vendors. When the problem is governance, you fix it once. When the problem is vendor performance without governance backing, you negotiate, audit, and renegotiate.
Third: Programs with distributed or absent decision-making authority move faster in the early weeks but slower overall. Decision cycles extend. Rework multiplies. Timeline recovery becomes a crisis narrative rather than a planned course correction.
What Control Actually Looks Like
Control is not about slowing things down. It is about moving with intention. It means defining success before you start. It means assigning decision rights so everyone knows who decides what. It means measuring progress against those definitions and course-correcting when the data tells you to. It means vendors understand the standards they are held to and know how performance will be measured. It means Kieran Engels’ philosophy at Seuss+ becomes the north star: clarity is the foundation for speed.
This is not risk aversion. It is risk prevention. When you have clear governance, you can move faster because you know what matters and what does not. You can say yes to opportunity without worrying it will unravel the program. You can push vendors harder because they understand the why behind the standards. You can make faster decisions because you have already defined decision authority.
Speed Shortcuts and Their Hidden Costs
| Shortcut Taken | Apparent Gain | Hidden Cost | What Control Looks Like Instead |
| Relaxed inclusion criteria | 30-40% faster enrollment | Loss of signal integrity, higher dropout rates | Precise subject targeting, clear selection rationale |
| Skipped database verification | 2-3 week acceleration to lock | Data quality issues resurface during analysis | Phased verification with stakeholder sign-off |
| Excluded stakeholder input from decisions | Faster decision cycles | Rework when stakeholders surface concerns later | Pre-defined decision authority, stakeholder alignment |
| Minimal vendor governance | Faster contracting | Performance drift, quality issues, extended recovery | Clear KPIs, regular governance forums, accountability |
| Loose timeline management | Flexibility in early weeks | Cascading delays, crisis-driven decision making | Clear milestones, planned buffer, course correction protocol |
Control is not friction. It is the foundation that allows motion.
Key Industry Data
Daily trial delays cost sponsors $600,000 to $8 million, and governance gaps that extend timelines by even a single week create measurable financial exposure. (Source: Tufts CSDD)
70% of clinical trials experience delays, many traceable to weak vendor governance structures rather than vendor performance alone. (Source: Tufts CSDD)
Between 50% and 60% of clinical trial activities are outsourced, making governance frameworks a core determinant of trial quality. (Source: IQVIA)
The Oversight Capability Maturity Model defines five levels of vendor governance maturity across 10 critical dimensions. (Source: Avoca/WCG)
The Clinical Trials Management Ecosystem maturity model identifies five levels of governance capability across 11 operational axes. (Source: Journal of Clinical and Translational Science)
Frequently Asked Questions
Watch for decision-making that accelerates without stakeholder alignment, vendor performance that drifts between governance forums, and timeline compression that is not backed by process discipline. If your team is frequently reworking earlier deliverables or discovering issues in QA that should have been caught upstream, speed is masking governance failure.
Yes. Control added retroactively slows you down. Control designed upfront accelerates you. The governance frameworks created at program launch should define decision authority, ownership, and measurement before execution begins. This front-load of clarity removes ambiguity that would otherwise surface as delays later.
Vendor performance is a governance output, not just an operational outcome. Clear governance includes defined KPIs, regular measurement cadence, explicit success criteria, and accountability structures. Programs with weak governance experience vendor issues that extend timelines by four to eight weeks. Strong governance prevents these issues or resolves them faster.
Decision rights are not about centralizing authority. They are about clarity. Define which decisions require consensus, which require consultation, and which are delegated to individuals. Include escalation paths for decisions that cross functional lines. The goal is speed with accountability, not speed with ambiguity.
Track rework rates, decision cycle time, vendor issue resolution time, and the frequency of late-stage discoveries. If you are moving fast but reworking frequently, you have lost control. If rework is rare but decisions slow, you have too much friction. The balance is found when you are moving fast and delivering clean work the first time.
About the Author
Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.
